Treatment of advanced malignant eccrine poroma with locoregional chemotherapy
E. De Bree, E. Volalakis, D. Tsetis, Y. Varthalitis,
J. Panagiotidis,
J. Romanos, D.D. Tsiftsis,
Y. Varthalitis
Department of Medical Oncology, District Hospital, Chania, Greece
Search for more papers by this authorJ. Panagiotidis
Pathology, University Hospital, Medical School of Crete, Herakleion, Greece
Search for more papers by this authorE. De Bree, E. Volalakis, D. Tsetis, Y. Varthalitis,
J. Panagiotidis,
J. Romanos, D.D. Tsiftsis,
Y. Varthalitis
Department of Medical Oncology, District Hospital, Chania, Greece
Search for more papers by this authorJ. Panagiotidis
Pathology, University Hospital, Medical School of Crete, Herakleion, Greece
Search for more papers by this authorE. de Bree MD.
E-mail: [email protected]
Conflicts of interest: None declared.
Summary
Malignant eccrine poroma is a rare disease with approximately 200 cases reported in the literature. Regional cutaneous and systemic metastases are rarely observed and their management has been generally unsuccessful. We report on a case in which topical 5-fluorouracil application and intra-arterial chemotherapy with docetaxel resulted in a histologically confirmed complete response of multiple regional skin metastases for more than 2 years. Despite intravenous administration of docetaxel, slow progression of systemic disease was observed.
References
- 1
Wick MR,
Coffin MC.
Adnexal carcinomas of the skin. I. Eccrine carcinomas.
Cancer
1985; 56: 1147–62.
10.1002/1097-0142(19850901)56:5<1147::AID-CNCR2820560532>3.0.CO;2-3 CAS PubMed Web of Science® Google Scholar
- 2 Pinkus H, Mehregan AH. Epidermotropic eccrine carcinoma: a case combining features of eccrine poroma and Paget's dermatosis. Arch Dermatol 1963; 88: 597–607.
- 3 Robson A, Greene J, Ansari N et al. Eccrine porocarcinoma (malignant eccrine poroma): a clinicopathologic study of 69 cases. Am J Surg Pathol 2001; 25: 710–20.DOI: 10.1097/00000478-200106000-00002
- 4 Poiares-Baptista A, Tellechea O, Reis JP et al. Porocarcinome eccrine: revue de 24 cas. Ann Dermatol Venereol 1993; 120: 107–15.
- 5 Mehregan AH, Hashimoto K, Rahbari H. Eccrine adenocarcinoma: clinicopathological study of 35 cases. Arch Dermatol 1983; 119: 104–14.DOI: 10.1001/archderm.119.2.104
- 6 Shaw M, McKee PH, Lowe D et al. Malignant eccrine poroma: a study of 27 cases. Br J Dermatol 1982; 107: 675–80.
- 7 Plunkett TA, Hanby AM, Miles DW, Rubens RD. Metastatic eccrine porocarcinoma: response to docetaxel (Taxotere) chemotherapy. Ann Oncol 2001; 12: 411–4.DOI: 10.1023/A:1011196615177
- 8 Huet P, Dandurand M, Pignodel C, Guillot B. Metastasizing eccrine porocarcinoma: report of a case and review of the literature. J Am Acad Dermatol 1996; 35: 860–4.DOI: 10.1016/S0190-9622(96)90105-X
- 9
Piedbois P,
Breau JL,
Morere JF,
Israel L.
Sweat gland carcinoma with bone and visceral metastases. Prolonged complete remission lasting 16 months as a result of chemotherapy.
Cancer
1987; 60: 170–2.
10.1002/1097-0142(19870715)60:2<170::AID-CNCR2820600208>3.0.CO;2-R CAS PubMed Web of Science® Google Scholar
- 10 Swanson DJ, Pazdur R, Sykes E. Metastatic sweat gland carcinoma: response to 5-fluorouracil infusion. J Surg Oncol 1989; 42: 69–72.
- 11 Permal S, Chemal N, Dhote R et al. Metastases pulmonaires revelatrices d'une tumeur cutanee rare: le porocarcinome eccrine. Rev Med Interne 2000; 21: 91–4.
- 12
Sridhar KS,
Benedetto P,
Otrakji CL,
Charyulu KK.
Response of eccrine adenocarcinoma to tamoxifen.
Cancer
1989; 64: 366–70.
10.1002/1097-0142(19890715)64:2<366::AID-CNCR2820640204>3.0.CO;2-R CAS PubMed Web of Science® Google Scholar
- 13 Maeda T, Mori H, Matsuo T et al. Malignant eccrine poroma with multiple visceral metastases: report of a case and autopsy findings. J Cutan Pathol 1996; 53: 566–70.
- 14 Grimme H, Petres A, Bergen E et al. Metastasizing porocarcinoma of the head with lethal outcome. Dermatology 1999; 198: 298–300.DOI: 10.1159/000018135
- 15 Magdum SA, O'Brien DP, O'Reilly G, Crooks D. Malignant eccrine poroma with spinal and cerebrospinal fluid metastases: case report. Neurosurgery 2001; 49: 1004–7.DOI: 10.1097/00006123-200110000-00042
- 16 Erel E, Tarr G, Butterworth MS, Butler PEM. Unusual metastatic spread of a malignant eccrine poroma. Dermatol Online J 2002; 8: 7.
- 17 Abenoza P, Ackerman BA. Porocarcinomas. In: Neoplasma with Eccrine Differentiation ( P Abenoza, BA Ackerman, eds). Philadelphia: Lea & Febiger, 1990; 415–31.
- 18
Harari PM,
Shimm DS,
Bangert JL et al.
The role of radiotherapy in the treatment of malignant sweat gland neoplasms.
Cancer
1990; 65: 1737–41.
10.1002/1097-0142(19900415)65:8<1737::AID-CNCR2820650813>3.0.CO;2-Q CAS PubMed Web of Science® Google Scholar
- 19 Barzi AS, Ruggeri S, Recchia F, Bertoldi I. Malignant metastatic eccrine poroma. Proposal for a new therapeutic protocol. Dermatol Surg 1997; 23: 267–72.
- 20 Roach M. A malignant eccrine poroma responds to isotretinoin (13-cis-retinoic acid). Ann Intern Med 1983; 99: 486–8.
- 21 Friedland M, Bajracharya A, Arlin A. Malignant eccrine poroma and isotretinoin. Ann Intern Med 1984; 100: 614.
- 22 Olieman AF, Lienard D, Eggermont AM et al. Hyperthermic isolated limb perfusion with tumor necrosis factor alpha, interferon gamma, and melphalan for locally advanced nonmelanoma skin tumors of the extremities: a multicenter study. Arch Surg 1999; 134: 303–7.DOI: 10.1001/archsurg.134.3.303
- 23 Briscoe KE, Grage T, Kennedy BJ. Sustained complete remission of metastatic sweat gland carcinoma following regional hyperthermic perfusion. JAMA 1978; 240: 51–2.
- 24 Guadagni S, Ruso F, Rossi RC et al. Deliberate hypoxic pelvic and limb chemoperfusion in the treatment of recurrent melanoma. Am J Surg 2002; 183: 28–36.DOI: 10.1016/S0002-9610(01)00841-8
- 25 Wang MQ, Dake MD, Wang ZP et al. Isolated lower extremity chemotherapeutic infusion for treatment of osteosarcoma: experimental study and preliminary clinical report. J Vasc Interv Radiol 2001; 12: 731–7.
- 26 Dummer R, Becker JC, Boser B et al. Successful therapy of metastatic eccrine poroma using perilesional interferon-α and interleukin-2. Arch Dermatol 1992; 128: 1127–8.DOI: 10.1001/archderm.128.8.1127
- 27 Goette DK. Topical chemotherapy with 5-fluorouracil. A review. J Am Acad Dermatol 1981; 4: 633–49.
- 28 Hamouda B, Jamila Z, Najet R et al. Topical 5-fluorouracil to treat multiple or unresectable facial squamous cell carcinomas in xeroderma pigmentosum. J Am Acad Dermatol 2001; 44: 1054.DOI: 10.1067/mjd.2001.113476
- 29 Robins P, Gupta AK. The use of topical fluorouracil to treat actinic keratosis. Cutis 2002; 70 (2 Suppl.): 4–7.
